New Delhi, Sept 18: Domestic pharma major Ranbaxy Laboratories on Wednesday announced the launch of a new cholesterol reducing drug Rosuvas. The drug will be used for lowering LDPL cholesterol as well as reducing triglycerides while raising HDL levels, a company release said.
The drug would compete in the Rs 150 crore statin market estimated to grow at 23 per cent annually.
Ranbaxy has already cornered a 20 per cent share in the segment with four brands and the new drug would consolidate its presence in the market.
"The introduction of Rosuvas will provide Indian doctors with the latest therapy in reduction of high cholesterol and also strengthen the company's leadership position in the highly competitive statin market", Regional director Malvinder Mohan Singh said. Bureau Report